Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
Abstract Background Heart failure (HF) is a common cardiovascular complication of type 2 diabetes (T2D). This secondary analysis investigated baseline factors and treatment differences associated with risk of hospitalization for HF (hHF), and the possible association between severe hypoglycemia and...
Main Authors: | Richard E. Pratley, Mansoor Husain, Ildiko Lingvay, Thomas R. Pieber, Thomas Mark, Hans A. Saevereid, Daniel Vega Møller, Bernard Zinman, the DEVOTE Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0960-8 |
Similar Items
-
Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study
by: Toshitaka Sawamura, et al.
Published: (2024-03-01) -
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017-04-01) -
Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
by: Eman N. Alhmoud, et al.
Published: (2024-01-01) -
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01) -
Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)